NCT06868459
Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Multicenter Registry
Enrolling by Invitation
Not specifiedAges 18–89ObservationalSarasota Memorial Health Care SystemInvestigator-initiated
~100 participants
Updated 2025-09-08 on ClinicalTrials.gov
What's tested:Data Collection
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
ThyPro-39 questionnaire
Measured over 6 months
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Study leadership
- Tamela Fonseca, PhD, RN, CCRC, NE-BC · STUDY_DIRECTOR · Sarasota Memorial Health Care System
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- ThyPro-39 questionnaire6 months
Change in quality of life as measured by ThyPro-39 questionnaire at 6-months (+/- 60). Responses to each statement are measured on a Likert scale ranging from '0= no symptoms or problems' to '4= severe symptoms or problems' based on the period of the last 4 weeks. Higher scores indicate greater impact on quality of life due to thyroid issues.
- Procedure related adverse events6 months
Safety as measured by the rate of procedure related adverse events as measured by SIR criteria at 2-weeks (+/- 7 days), 3- (+/- 30 days) and 6-months (+/- 60 days) post PED-TAE using TriNav treatment.